Results 11 to 20 of about 12,087 (179)

Diazoxide-Induced Hypertrichosis in a Neonate With Transient Hyperinsulinism

open access: yesClinical Medicine Insights: Case Reports, 2023
Diazoxide is one of the FDA-approved pharmacologic treatments for hyperinsulinemic hypoglycemia, however, its adverse effects in infants are not well described. We reported a 37-week-old boy with the diagnosis of hypoglycemia.
Seyyed Javad Boskabadi   +3 more
doaj   +1 more source

Diazoxide Post-conditioning Activates the HIF-1/HRE Pathway to Induce Myocardial Protection in Hypoxic/Reoxygenated Cardiomyocytes

open access: yesFrontiers in Cardiovascular Medicine, 2021
Background: Previous studies have shown that diazoxide can protect against myocardial ischemia-reperfusion injury (MIRI). The intranuclear hypoxia-inducible factor-1 (HIF-1)/hypoxia-response element (HRE) pathway has been shown to withstand cellular ...
Xi-Yuan Chen   +9 more
doaj   +1 more source

Kir1.1 and SUR1 are not implicated as subunits of an adenosine triphosphate-sensitive potassium channel involved in diazoxide cardioprotectionCentral MessagePerspective

open access: yesJTCVS Open, 2023
Objective: The adenosine triphosphate-sensitive potassium channel opener diazoxide mimics ischemic preconditioning and is cardioprotective. Clarification of diazoxide's site and mechanism of action could lead to targeted pharmacologic therapies for ...
Jie Wang, MD   +12 more
doaj   +1 more source

Evaluation of spasmolytic effects of naringenin on ileum contraction and intestinal charcoal meal transit: Involvement of ATP-sensitive K+ channels [PDF]

open access: yesJournal of HerbMed Pharmacology, 2022
Introduction: Naringenin is a flavonoid constituent of many herbal plants, including citreous fruits. Biological studies have suggested various therapeutic effects for naringenin, including protective effects on gastrointestinal (GI) motility.
Hassan Sadraei   +2 more
doaj   +1 more source

Ubiquinol-cytochrome c reductase core protein 1 may be involved in delayed cardioprotection from preconditioning induced by diazoxide. [PDF]

open access: yesPLoS ONE, 2017
This study aimed to use long-term diazoxide treatment to establish a loss-of-cardioprotection model and then perform proteomics analysis to explore which proteins of mitochondrial inner membrane (MIM) are potentially involved in delayed cardioprotection.
Zonghong Long   +7 more
doaj   +1 more source

Recurrent Hypoglycemia in Two Late‐Preterm Infants With Transitional Disorder of Glucose Mobilization—Case Series [PDF]

open access: yesClin Case Rep
Timeline of events. ABSTRACT Great emphasis is placed upon addressing hyperinsulinism in at‐risk infants with recurrent hypoglycemia. We report two preterm infants with recurrent nonhyperinsulinemic hypoglycemia due to transient impairment of glucose mobilization, warranting diazoxide use.
Chandran S, Ting Y, Abhirami S, Yap F.
europepmc   +2 more sources

ATP—Sensitive Potassium Channel Opener Diazoxide Reduces Myocardial Stunning in a Porcine Regional With Subsequent Global Ischemia Model

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background ATP‐sensitive potassium channels are inhibited by ATP and open during metabolic stress, providing endogenous myocardial protection. Pharmacologic opening of ATP potassium channels with diazoxide preserves myocardial function following ...
Ana K. Velez   +10 more
doaj   +1 more source

Pulmonary hypertension associated with diazoxide: the SUR1 paradox

open access: yesERJ Open Research, 2023
The ATP-sensitive potassium channels and their regulatory subunits, sulfonylurea receptor 1 (SUR1/Kir6.2) and SUR2/Kir6.1, contribute to the pathophysiology of pulmonary hypertension (PH).
David Montani   +7 more
doaj   +1 more source

A Rare Side Effect of Diazoxide Therapy: Pulmonary Hipertension

open access: yesJournal of Behçet Uz Children's Hospital, 2020
We present a newborn diagnosed with Beckwith-Wiedemann syndrome and hypoglycemia, and developed pulmonary hypertension due to initiated diazoxide treatment because of these indications.
Alper Hazım Gürsu   +4 more
doaj   +1 more source

Diazoxide-associated pulmonary hypertension in a patient with noncompaction cardiomyopathy

open access: yesPulmonary Circulation, 2021
Development of pulmonary hypertension after initiation of diazoxide for the treatment of neonatal hyperinsulinemic hypoglycemia is a rare, but previously described association.
Rachel T. Sullivan   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy